Market capitalization | GBP5.00b |
Enterprise Value | GBP5.82b |
P/E (TTM) P/E ratio | 26.14 |
EV/FCF (TTM) EV/FCF | 30.64 |
EV/Sales (TTM) EV/Sales | 3.51 |
P/S ratio (TTM) P/S ratio | 3.02 |
P/B ratio (TTM) P/B ratio | 4.33 |
Dividend yield | 2.35% |
Last dividend (FY23) | GBP1.60 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
18 Analysts have issued a Spirax-Sarco Engineering forecast:
18 Analysts have issued a Spirax-Sarco Engineering forecast:
Jun '24 |
+/-
%
|
||
Revenue | 1,659 1,659 |
3%
3%
|
|
Gross Profit | 302 302 |
11%
11%
|
|
EBITDA | 387 387 |
12%
12%
|
EBIT (Operating Income) EBIT | 302 302 |
11%
11%
|
Net Profit | 192 192 |
9%
9%
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Spirax-Sarco Engineering Plc provides industrial and commercial steam systems, electrical thermal energy solutions and niche peristaltic pumps and associated fluid path technologies. It operates its business through the following segments: Steam Specialties, Electric Thermal Solutions and Watson-Marlow. The Steam Specialties segment supplies engineered solutions for the design, maintenance and operation of efficient industrial and commercial steam systems. The Electric Thermal Solutions segment process heating and temperature management solutions, including industrial heaters and systems, heat tracing and component technologies. The Watson-Marlow segment provides peristaltic and selective niche pumps and systems, specializing not only in the design and manufacture of the most advanced pumps and tubing, but also in the application of those pumps to its customer's processes. The company was founded on June 19, 1952 and is headquartered in Cheltenham, the United Kingdom.
Head office | United Kingdom |
CEO | Nimesh Patel |
Employees | 10,000 |
Founded | 1952 |
Website | www.spiraxsarcoengineering.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.